In this study, we sought to determine whether FcRH5, a surface antigen highly expressed in malignant plasma cells could be used as a potential target for CAR-T cells against MM maintaining or lacking BCMA antigen. The gene discussed is FCRL5; the disease is Miyoshi myopathy.